Previous 10 | Next 10 |
Lantern Pharma's Board of Directors Names Maria Maccecchini, Ph.D. as a Director Nominee to Lantern's Board of Directors PR Newswire DALLAS , April 26, 2022 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN ), a clinical stage biopharmaceutical co...
Lantern Pharma to Report First Quarter 2022 Operating & Financial Results on May 3rd, 2022 at 4:30 p.m. ET Lantern Pharma to Report First Quarter 2022 Operating & Financial Results on May 3rd, 2022 at 4:30 p.m. ET PR Newswire DALLAS , April 22, 2022 /...
ORLANDO, FL / ACCESSWIRE / April 14, 2022 / RedChip Companies, Inc. today announced that Lantern Pharma (NASDAQ:LTRN),a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (ML) platform to transform the cost, pace,...
Lantern Pharma (NASDAQ:LTRN) board authorized an extension through July 31, 2022 of Lantern's existing share repurchase program to acquire up to $7M of its stock. Since program initiation in November 2021, 475,157 shares have been repurchased. Total expenditures for share repurchases fro...
Lantern Pharma Announces Extension of Existing Share Repurchase Program PR Newswire DALLAS , March 22, 2022 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artif...
Lantern Pharma to Present Positive Preclinical Data on the Effectiveness of LP-184 in Brain Metastases at the American Association of Cancer Research (AACR) Annual Meeting PR Newswire LP-184 demonstrated anti-tumor activity in brain metastases cell models from lung, sk...
The following slide deck was published by Lantern Pharma Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Lantern Pharma Inc. 2021 Q4 - Results - Earnings Call Presentation
Lantern Pharma Inc. (LTRN) Q4 2021 Earnings Conference Call March 10, 2022, 4:30 PM ET Company Participants Nicole Leber - Investor Relations Panna Sharma - President and CEO David Margrave - Chief Financial Officer Kishor Bhatia - Chief Scientific Officer Conference Call Participants Michael...
Lantern Pharma press release (NASDAQ:LTRN): Q4 GAAP EPS of -$1.13 misses by $0.74. Q4 Cash and Cash equivalents $70.7M For further details see: Lantern Pharma GAAP EPS of -$1.13 misses by $0.74
Lantern Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Operational Highlights -- RADR®, Lantern's proprietary A.I. and machine learning platform, grew from 1.2 billion to over 18 billion data points, enhancing its precision, insights, and capabilit...
News, Short Squeeze, Breakout and More Instantly...
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a significant advancement towards the development of a diagn...
LP-284 is currently in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR ® , as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma and certain genomically defined sarcomas. LP-284 is the third molecule brou...
Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 on-track for the second half of 2024. Obtained regulatory allowance to begin Phase 2 Harmonic™ clinical trial enrollment in Japan and Taiwan where approximately 30-35+% ...